1. Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice
   Ambica Parmar et al, 2020, Critical Reviews in Oncology/Hematology CrossRef
2. Aproximación a los metanálisis de comparación de múltiples tratamientos: una revisión de la literatura
   Mateo Zuluaga Gómez et al, 2019, Medicina UPB CrossRef
3. Efficacy of axitinib rechallenge in metastatic renal cell carcinoma
   Kotaro Suzuki et al, 2021, International Journal of Urology CrossRef
4. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)
   Maria Giuseppa Vitale et al, 2019, Tumori Journal CrossRef
5. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
   Álvaro Pinto et al, 2022, Clinical Genitourinary Cancer CrossRef
6. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis
   Elvira Schmidt et al, 2018, Targeted Oncology CrossRef
7. Role of axitinib and other tyrosine kinase inhibitors in the management of metastatic renal cell carcinoma
   Nishtha Khatri et al, 2022, Journal of Current Oncology CrossRef
8. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
   Gaetano Facchini et al, 2019, Journal of Translational Medicine CrossRef
9. Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
   Carmine D'Aniello et al, 2016, Frontiers in Pharmacology CrossRef
10. Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs
    Xiaofeng Chang et al, 2016, Oncotarget CrossRef
11. Induction of Epithelial-Mesenchymal Transition via Activation of Epidermal Growth Factor Receptor Contributes to Sunitinib Resistance in Human Renal Cell Carcinoma Cell Lines
    Atsushi Mizumoto et al, 2015, Journal of Pharmacology and Experimental Therapeutics CrossRef
12. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma
    Melissa Bersanelli et al, 2021, Expert Review of Anticancer Therapy CrossRef
13. Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Jacopo Giuliani et al, 2019, Clinical Genitourinary Cancer CrossRef
14. Sorafenib
    Giuseppe Tridente, 2017, Adverse Events and Oncotargeted Kinase Inhibitors CrossRef
15. Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma
    Jacopo Giuliani et al, 2018, Clinical Genitourinary Cancer CrossRef